首頁 > 市場調查報告書 > 製藥

疫苗

市場調查報告書

商品編碼

1562320

2030 年亞太地區人類疫苗佐劑市場預測 - 區域分析 - 按類型、應用（流感、肝炎、人類乳突病毒等）和最終用戶

Asia Pacific Human Vaccine Adjuvants Market Forecast to 2030 - Regional Analysis - by Type, Application (Influenza, Hepatitis, Human papilloma virus, and Others), and End User

出版日期: 2024年07月04日 | 出版商:

The Insight Partners | 英文 113 Pages | 訂單完成後即時交付

價格

簡介目錄圖表

2022年亞太人用疫苗佐劑市場估值為3.3019億美元，預計2030年將達到10.0852億美元；預計2022年至2030年複合年成長率為15.0%。

不斷成長的製藥業推動亞太地區人類疫苗佐劑市場

不斷擴大的製藥業預計將對佐劑的需求產生積極影響，因為它們可以提高疫苗的功效和安全性。製藥業日益關注傳染病、癌症和自體免疫疾病，為開發針對這些特定疾病領域的個人化疫苗和佐劑提供了平台。這為佐劑製造商提供了開發專門佐劑以增強對這些疾病疫苗的免疫反應的機會。根據 EFPIA 的數據，巴西、中國和印度製藥業在 2016-2021 年期間分別成長了 11.7%、6.7% 和 11.8%，而排名前五名的歐盟市場和美國市場則錄得平均市場成長率分別為5.8 %和5.6%。此外，根據印度品牌資產基金會 (IBEF) 的數據，印度是全球製藥業的一個主要且正在崛起的參與者。該國是世界上最大的學名藥貿易國，佔全球供應量的近20%。它供應了全球約 50% 的疫苗接種需求。國內製藥業包括 3,000 家製藥公司和約 10,500 個製造單位。根據印度政府的官方數據，印度醫藥產業價值近500億美元，其中超過250億美元來自出口。印度佔世界學名藥出口的 20% 左右。此外，日本是世界上最大的藥品市場之一。根據厚生勞動省（MHLW）年度藥品生產統計數據，2020 年日本處方藥和非處方藥市場規模為 1,070 億美元。隨著產業不斷發展和創新，對能夠支持個人化疫苗開發的佐劑的需求不斷增加，推動亞太地區人類疫苗佐劑市場的顯著成長和投資。因此，全球不斷成長的製藥業可能會在未來幾年為亞太地區人類疫苗佐劑市場創造利潤豐厚的成長機會。

亞太地區人類疫苗佐劑市場概況

中國對醫療保健和製藥業進行了大量投資，旨在增強國內生產、研究和開發能力。這一戰略重點使該國成為亞太人類疫苗佐劑市場的關鍵參與者。此外，中國是世界上人口最稠密的國家之一；目前人口約14.1億。根據2020年10月發布的最新全球疾病負擔（GBD）研究顯示，該國人口容易罹患各種傳染病、慢性和急性疾病。

傳染病流行率的增加預計將刺激疫苗接種的需求。根據ICO/IARC資訊中心2023年HPV與癌症資訊中心的報告，中國有5.824億15歲及以上女性有HPV相關子宮頸癌的風險。據估計，中國普通人群中約有 3.8% 的女性在特定時間攜帶子宮頸 HPV-16/18 感染，69.1% 的侵襲性子宮頸癌歸因於 HPV 16 或 18。推動亞太地區人類疫苗佐劑市場的成長。

亞太地區人類疫苗佐劑市場收入及 2030 年預測（百萬美元）

亞太地區人類疫苗佐劑市場區隔

亞太地區人類疫苗佐劑市場按類型、應用、最終用戶和國家分類。

根據類型，亞太人疫苗佐劑市場分為顆粒佐劑、乳液佐劑、組合佐劑等。 2022 年，顆粒助劑領域佔最大的市場佔有率。

從應用來看，亞太人用疫苗佐劑市場分為流感、肝炎、人類乳突病毒（HPV）等。 2022 年，流感細分市場佔據最大市場。

以最終用戶分類，亞太地區人類疫苗佐劑市場分為製藥和生技公司、CMO 和 CRO 等。 2022 年，製藥和生物技術公司領域佔據最大的市場佔有率。

依國家分類，亞太地區人類疫苗佐劑市場分為日本、中國、印度、澳洲、韓國和亞太其他地區。 2022年，中國在亞太地區人類疫苗佐劑市場佔有率中佔據主導地位。

Croda International Plc、CSL Ltd、Dynavax Technologies Corp、Hawaii Biotech Inc、Novartis AG、Novavax Inc、Phibro Animal Health Corp、Seppic SA 和 SPI Pharma Inc 是亞太地區人類疫苗佐劑市場上的一些領先公司。

The expanding pharmaceutical industry is expected to positively influence the demand for adjuvants as they can improve the efficacy and safety of vaccines. The pharmaceutical industry's increasing focus on infectious diseases, cancer, and autoimmune disorders provides a platform for developing personalized vaccines and adjuvants targeted at these specific disease areas. This offers an opportunity for adjuvant manufacturers to develop specialized adjuvants to enhance the immune response to vaccines for these diseases. According to the EFPIA, the Brazilian, Chinese, and Indian pharmaceutical industries grew by 11.7%, 6.7%, and 11.8% during the 2016-2021 period, respectively, compared to the top five European Union markets and the US market, which recorded an average market growth of 5.8% and 5.6%, respectively. Furthermore, as per the India Brand Equity Foundation (IBEF), India is a major and rising global pharmaceutical industry player. The country is the world's largest trader of generic medications, accounting for nearly 20% of the worldwide supply by volume. It supplies ~50% of the global vaccination demand. The domestic pharmaceutical industry includes a network of 3,000 drug companies and ~10,500 manufacturing units. Based on official figures from the Indian government, the pharmaceutical sector in India is valued at nearly US$ 50 billion, of which over US$ 25 billion is derived from exports. India accounts for ~20% of the world's generic medicine exports. Further, Japan is one of the largest pharmaceutical markets in the world. According to the Ministry of Health, Labor and Welfare's (MHLW) Annual Pharmaceutical Production Statistics, the Japanese market for prescription and nonprescription pharmaceuticals in 2020 was US$ 107 billion. As the industry continues to evolve and innovate, there is an increasing demand for adjuvants that can support the development of personalized vaccines, driving significant growth and investment in the Asia Pacific human vaccine adjuvants market. Thus, the growing pharmaceutical industry worldwide will likely create lucrative growth opportunities for the Asia Pacific human vaccine adjuvants market in the coming years.

Asia Pacific Human Vaccine Adjuvants Market Overview

China has invested heavily in its healthcare and pharmaceutical industries, aiming to bolster domestic production, research, and development capabilities. This strategic focus has positioned the country as a key player in the Asia Pacific human vaccine adjuvants market. Additionally, China is among the most densely populated countries in the world; the current population is ~1.41 billion. According to the latest Global Burden of Disease (GBD) study published in October 2020, the population in the country is prone to various infectious, chronic, and acute diseases.

An increase in the prevalence of infectious diseases is expected to fuel the demand for vaccinations. According to a report by the ICO/IARC Information Centre on HPV and Cancer in 2023, China has a population of 582.4 million women aged 15 years and older who are at risk of developing HPV-related cervical cancer. About 3.8% of women in China in the general population are estimated to harbor cervical HPV-16/18 infection at a given time, and 69.1% of invasive cervical cancers are attributed to HPVs 16 or 18. Thus, the rising number of patients and the increasing demand for vaccines for treatment are also expected to boost the Asia Pacific human vaccine adjuvants market growth.

Asia Pacific Human Vaccine Adjuvants Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Human Vaccine Adjuvants Market Segmentation

The Asia Pacific human vaccine adjuvants market is categorized into type, application, end user, and country.

Based on type, the Asia Pacific human vaccine adjuvants market is segmented particulate adjuvant, emulsion adjuvant, combination adjuvant, and others. The particulate adjuvant segment held the largest market share in 2022.

In terms of application, the Asia Pacific human vaccine adjuvants market is categorized into influenza, hepatitis, Human Papilloma Virus (HPV), and others. The influenza segment held the largest market share in 2022.

By end user, the Asia Pacific human vaccine adjuvants market is segmented into pharmaceutical and biotechnology companies, CMOs and CROs, and others. The pharmaceutical and biotechnology companies segment held the largest market share in 2022.

By country, the Asia Pacific human vaccine adjuvants market is segmented into Japan, China, India, Australia, South Korea, and the Rest of Asia Pacific. China dominated the Asia Pacific human vaccine adjuvants market share in 2022.

Croda International Plc, CSL Ltd, Dynavax Technologies Corp, Hawaii Biotech Inc, Novartis AG, Novavax Inc, Phibro Animal Health Corp, Seppic SA, and SPI Pharma Inc are some of the leading companies operating in the Asia Pacific human vaccine adjuvants market.

1. Introduction

1.1 The Insight Partners Research Report Guidance
1.2 Market Segmentation

2. Executive Summary

2.1 Key Insights

3. Research Methodology

3.1 Coverage
3.2 Secondary Research
3.3 Primary Research

4. Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics

4.1 Asia Pacific Human Vaccine Adjuvants Market - Key Market Dynamics
4.2 Market Drivers
- 4.2.1 Rising Prevalence of Chronic Diseases
- 4.2.2 Growing Focus on Immunization Programs
4.3 Market Restraints
- 4.3.1 Manufacturing Complexities and Regulatory Challenges
4.4 Market Opportunities
- 4.4.1 Growing Pharmaceutical Industry
4.5 Future Trends
- 4.5.1 Rising Trend of Personalized Vaccines
4.6 Impact of Drivers and Restraints:

5. Human Vaccine Adjuvants Market - Asia Pacific Market Analysis

5.1 Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2020 - 2030
5.2 Asia Pacific Human Vaccine Adjuvants Market Forecast Analysis

6. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Type

6.1 Particulate Adjuvant
- 6.1.1 Overview
- 6.1.2 Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.2 Emulsion Adjuvant
- 6.2.1 Overview
- 6.2.2 Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.3 Combination Adjuvant
- 6.3.1 Overview
- 6.3.2 Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
6.4 Others
- 6.4.1 Overview
- 6.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

7. Asia Pacific Human Vaccine Adjuvants Market Analysis - by Application

7.1 Influenza
- 7.1.1 Overview
- 7.1.2 Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.2 Hepatitis
- 7.2.1 Overview
- 7.2.2 Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.3 Human papilloma virus (HPV)
- 7.3.1 Overview
- 7.3.2 Human papilloma virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
7.4 Others
- 7.4.1 Overview
- 7.4.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

8. Asia Pacific Human Vaccine Adjuvants Market Analysis - by End User

8.1 Pharmaceutical and Biotechnology Companies
- 8.1.1 Overview
- 8.1.2 Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.2 CMOs and CROs
- 8.2.1 Overview
- 8.2.2 CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
8.3 Others
- 8.3.1 Overview
- 8.3.2 Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)

9. Asia Pacific Human Vaccine Adjuvants Market - Country Analysis

9.1 Asia Pacific
- 9.1.1 Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
  - 9.1.1.1 China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.1.1 China Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.1.2 China Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.1.3 China Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.2 Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.2.1 Japan Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.2.2 Japan Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.2.3 Japan Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.3 India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.3.1 India Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.3.2 India Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.3.3 India Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.4 Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.4.1 Australia Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.4.2 Australia Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.4.3 Australia Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.5 South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.5.1 South Korea Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.5.2 South Korea Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.5.3 South Korea Human Vaccine Adjuvants Market Breakdown, by End User
  - 9.1.1.6 Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
    - 9.1.1.6.1 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Type
    - 9.1.1.6.2 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Application
    - 9.1.1.6.3 Rest of Asia Pacific Human Vaccine Adjuvants Market Breakdown, by End User

10. Industry Landscape

10.1 Overview

11. Company Profiles

11.1 Novartis AG
- 11.1.1 Key Facts
- 11.1.2 Business Description
- 11.1.3 Products and Services
- 11.1.4 Financial Overview
- 11.1.5 SWOT Analysis
- 11.1.6 Key Developments
11.2 Dynavax Technologies Corp
- 11.2.1 Key Facts
- 11.2.2 Business Description
- 11.2.3 Products and Services
- 11.2.4 Financial Overview
- 11.2.5 SWOT Analysis
- 11.2.6 Key Developments
11.3 CSL Ltd
- 11.3.1 Key Facts
- 11.3.2 Business Description
- 11.3.3 Products and Services
- 11.3.4 Financial Overview
- 11.3.5 SWOT Analysis
- 11.3.6 Key Developments
11.4 Seppic SA
- 11.4.1 Key Facts
- 11.4.2 Business Description
- 11.4.3 Products and Services
- 11.4.4 Financial Overview
- 11.4.5 SWOT Analysis
- 11.4.6 Key Developments
11.5 SPI Pharma Inc
- 11.5.1 Key Facts
- 11.5.2 Business Description
- 11.5.3 Products and Services
- 11.5.4 Financial Overview
- 11.5.5 SWOT Analysis
- 11.5.6 Key Developments
11.6 Hawaii Biotech Inc
- 11.6.1 Key Facts
- 11.6.2 Business Description
- 11.6.3 Products and Services
- 11.6.4 Financial Overview
- 11.6.5 SWOT Analysis
- 11.6.6 Key Developments
11.7 Croda International Plc
- 11.7.1 Key Facts
- 11.7.2 Business Description
- 11.7.3 Products and Services
- 11.7.4 Financial Overview
- 11.7.5 SWOT Analysis
- 11.7.6 Key Developments
11.8 Novavax Inc
- 11.8.1 Key Facts
- 11.8.2 Business Description
- 11.8.3 Products and Services
- 11.8.4 Financial Overview
- 11.8.5 SWOT Analysis
- 11.8.6 Key Developments
11.9 Phibro Animal Health Corp
- 11.9.1 Key Facts
- 11.9.2 Business Description
- 11.9.3 Products and Services
- 11.9.4 Financial Overview
- 11.9.5 SWOT Analysis
- 11.9.6 Key Developments

12. Appendix

12.1 About The Insight Partners
12.2 Glossary of Terms

簡介目錄圖表

List Of Tables

Table 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation
Table 2. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Table 3. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Type
Table 4. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by Application
Table 5. Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million) - by End User
Table 6. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 7. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 8. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 9. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 10. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 11. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 12. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 13. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 14. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 15. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 16. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 17. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 18. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 19. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 20. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 21. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Type
Table 22. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by Application
Table 23. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million) - by End User
Table 24. Recent Growth Strategies in the Human Vaccine Adjuvants Market
Table 25. Glossary of Terms, Human Vaccine Adjuvants Market

List Of Figures

Figure 1. Asia Pacific Human Vaccine Adjuvants Market Segmentation, by Country
Figure 2. Impact Analysis of Drivers and Restraints
Figure 3. Asia Pacific Human Vaccine Adjuvants Market Revenue (US$ Million), 2022 - 2030
Figure 4. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Type (2022 and 2030)
Figure 5. Particulate Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 6. Emulsion Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 7. Combination Adjuvant: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 8. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by Application (2022 and 2030)
Figure 10. Influenza: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 11. Hepatitis: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 12. Human Papilloma Virus (HPV): Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Human Vaccine Adjuvants Market Share (%) - by End User (2022 and 2030)
Figure 15. Pharmaceutical and Biotechnology Companies: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 16. CMOs and CROs: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 17. Others: Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030 (US$ Million)
Figure 18. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries - Revenue (2022) (US$ Million)
Figure 19. Asia Pacific Human Vaccine Adjuvants Market Breakdown, by Key Countries, 2022 and 2030 (%)
Figure 20. China Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 21. Japan Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 22. India Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 23. Australia Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 24. South Korea Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)
Figure 25. Rest of Asia Pacific Human Vaccine Adjuvants Market - Revenue and Forecast to 2030(US$ Million)